770 results match your criteria Isoniazid Hepatotoxicity


Isoniazid prophylaxis in liver transplant recipient with latent tuberculosis; Is it harmful for transplanted liver?

Transpl Infect Dis 2022 May 17. Epub 2022 May 17.

Abu Ali Sina Organ Transplant Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Background: Liver transplantation (LT) is considered the only treatment for patients with end-stage liver disease and, despite its incredible impacts on the patients' health status, places them in an immunocompromised state in which opportunistic infection would find a way to present. Latent Tuberculosis Infection (LTBI) is the most common form of TB and can be diagnosed through Tuberculin Skin Test (TST) or Interferon-Gamma Release Assays (IGRA). LT recipients are at significant risk of TB activation. Read More

View Article and Full-Text PDF

Severe Respiratory Failure Due to Pulmonary BCGosis in a Patient Treated for Superficial Bladder Cancer.

Diagnostics (Basel) 2022 Apr 7;12(4). Epub 2022 Apr 7.

1st Department of Lung Diseases, National Research Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland.

Intra-vesical instillations with bacillus Calmette-Guerin (BCG) are the established adjuvant therapy for superficial bladder cancer. Although generally safe and well tolerated, they may cause a range of different, local, and systemic complications. We present a patient treated with BCG instillations for three years, who was admitted to our hospital due to fever, hemoptysis, pleuritic chest pain and progressive dyspnea. Read More

View Article and Full-Text PDF

Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis.

J Pharm Pharmacol 2022 Mar 30. Epub 2022 Mar 30.

Department of Pharmacy, Federal University of Paraná, Curitiba, Brazil.

Objectives: To evaluate and update the evidence on the comparative efficacy and safety of antimicrobial drugs regimens for treating pulmonary drug-susceptible tuberculosis (DS-TB).

Methods: A systematic review was performed with searches in PubMed and Scopus (PROSPERO-CRD42019141463). We included randomised controlled trials comparing the effect of any antimicrobial regimen lasting at least 2 weeks. Read More

View Article and Full-Text PDF

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis.

Cureus 2022 Feb 21;14(2):e22452. Epub 2022 Feb 21.

Hepatology, Northwell Health, Long Island Jewish Medical Center, New Hyde Park, USA.

Isoniazid (INH) is widely used for latent despite the known risk of liver injury, with severe hepatitis occurring in up to 1% of patients. We report a patient who presented with two weeks of anorexia, nausea, and jaundice following six months of INH monotherapy for latent tuberculosis (TB). After other causes of liver injury were ruled out, she underwent a liver biopsy showing submassive necrosis, hepatocellular dropout, and lobular inflammation with no evidence of fibrosis. Read More

View Article and Full-Text PDF
February 2022

Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research.

Mol Genet Genomics 2022 Mar 11;297(2):407-417. Epub 2022 Feb 11.

Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education, School of Life Sciences, Northwest University, Xi'an, 710069, Shaanxi, China.

Previous studies have shown that the frequency of very important pharmacogenomic (VIP) genes varies in different populations which leads to the diversities in drug efficacy, safety, and the risk associated with adverse drug reactions (ADRs). The purpose of this study was to identify the distribution differences of VIP variants between the Li population and the other 13 populations. Based on the Pharmacogenomics Knowledgebase database (PhamGKB), we successfully genotyped 52 VIP variants within 27 genes in 200 unrelated Li population. Read More

View Article and Full-Text PDF

Effects of Solanum lycopersicum L. (tomato) against isoniazid and rifampicin induced hepatotoxicity in wistar albino rats.

Braz J Biol 2022 7;84:e254552. Epub 2022 Feb 7.

COMSATS University Islamabad, Department of Pharmacy, Lahore, Pakistan.

Anti-tuberculosis drugs are reported to cause hepatotoxicity, which varies from asymptomatic rise of the hepatic enzymes. Hepatoprotective plants plays important role to protect liver. This study investigated the hepatoprotective potential of the Solanum lycopersicum in rats intoxicated with Isoniazid and Rifampicin (INH+RIF) to induce hepatotoxicity. Read More

View Article and Full-Text PDF
February 2022

[Association between isoniazid induced hepatotoxicity and host N-acetyltransferase 2 polymorphisms].

Zhonghua Jie He He Hu Xi Za Zhi 2022 Feb;45(2):227-232

Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.

Isoniazid(INH, H) has been a key drug for treating drug-susceptible tuberculosis (TB) for nearly seventy years. The differences in the pharmacokinetic(PK) might affect INH absorption. Low plasma concentration is related to less treatment outcomes and , but higher plasma concentrations can induce hepatotoxicity or death. Read More

View Article and Full-Text PDF
February 2022

Curcumin attenuates isoniazid-induced hepatotoxicity by upregulating the SIRT1/PGC-1α/NRF1 pathway.

J Appl Toxicol 2022 Jan 14. Epub 2022 Jan 14.

Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.

As a serious infectious disease, tuberculosis threatens global public health. Isoniazid is the first-line drug not only in active tuberculosis but also in its prevention. Severe hepatotoxicity greatly limits its use. Read More

View Article and Full-Text PDF
January 2022

Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury mitochondrial or other mechanisms.

Acta Pharm Sin B 2021 Dec 7;11(12):3857-3868. Epub 2021 Jun 7.

University of Rhode Island, College of Pharmacy, Kingston, RI 02881, USA.

Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, especially in idiosyncratic liver injury. This study examined liver injury reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) for drugs associated with hepatotoxicity mitochondrial mechanisms compared with non-mitochondrial mechanisms of toxicity. Read More

View Article and Full-Text PDF
December 2021

Engineering a Ratiometric Photoacoustic Probe with a Hepatocyte-Specific Targeting Ability for Liver Injury Imaging.

Anal Chem 2022 01 5;94(2):1474-1481. Epub 2022 Jan 5.

State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China.

In situ imaging of biological indicators is imperative for pathological research by utilizing an activatable photoacoustic (PA) probe. However, precise imaging in actual applications is hampered by the inevitable poor accumulation and low sensitivity. Herein, an amphiphilic molecular probe () was rationally constructed as proof of concept for in situ imaging of drug-induced liver injury, which consists of a hydrophilic target unit and a superoxide anion radical (O)-sensitive small-molecule PA moiety. Read More

View Article and Full-Text PDF
January 2022

The cleavage kinetics of hydrazide derivatives of isoniazid by HPLC-UV/DAD and its impact on activity against Mycobacterium tuberculosis.

J Chromatogr B Analyt Technol Biomed Life Sci 2022 Jan 9;1188:123080. Epub 2021 Dec 9.

Programa de Pós-Graduação em Química - Instituto de Química - Universidade Federal Fluminense - Outeiro de São João Batista, s/n, Valonguinho, Centro, Niterói, RJ, CEP 24020-141, Brazil. Electronic address:

Isoniazid is a first-line drug for the treatment of tuberculosis, a bacterial disease caused by Mycobacterium tuberculosis. Its terminal amino group is highly reactive, leading to significant metabolic deactivation, drug interactions and hepatotoxicity. It is speculated that the activity of isoniazid derivatives is, in part, related to the cleavage of the protecting group. Read More

View Article and Full-Text PDF
January 2022

Incidence of adverse drug events among patients on second line anti-tuberculosis regimen in the littoral region of cameroon.

Int J Mycobacteriol 2021 Oct-Dec;10(4):463-468

Department of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.

Background: An adverse drug event (ADE) is an injury resulting from medical intervention associated with a drug. This study assesses the incidence of ADEs among participants on second-line drugs for tuberculosis (TB) in Cameroon.

Methods: This was a longitudinal observational study including 65 participants and carried out from January 2017 to December 2017. Read More

View Article and Full-Text PDF
January 2022

miR-15a-3p Protects Against Isoniazid-Induced Liver Injury Suppressing -Acetyltransferase 2 Expression.

Front Mol Biosci 2021 23;8:752072. Epub 2021 Nov 23.

School of Public Health, Qingdao University, Qingdao, China.

Isoniazid (INH), an effective first-line drug for tuberculosis treatment, has been reported to be associated with hepatotoxicity for decades, but the underlying mechanisms are poorly understood. -acetyltransferase 2 (NAT2) is a Phase II enzyme that specifically catalyzes the acetylation of INH, and NAT2 expression/activity play pivotal roles in INH metabolism, drug efficacy, and toxicity. In this study, we systematically investigated the regulatory roles of microRNA (miRNA) in expression and INH-induced liver injury via a series of , , and analyses. Read More

View Article and Full-Text PDF
November 2021

High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.

Int J Infect Dis 2022 Feb 30;115:142-148. Epub 2021 Nov 30.

Hubei Provincial Center for Disease Control and Prevention, China. Electronic address:

Setting: The shorter treatment regimen (STR) for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) has achieved successful outcomes in many countries. However, there are few studies on high-dose gatifloxacin-based STR with adverse drug reactions (ADRs) and management.

Design: A prospective observational study was conducted with MDR/RR-TB patients who were treated with a standardized 9 or 12 - month regimen: including gatifloxacin (Gfx), clofazimine (Cfz), ethambutol (EMB), and pyrazinamide (PZA), and supplemented by amikacin (Am), isoniazid (INH), and prothionamide (Pto) during an intensive phase of 4 or 6 - month. Read More

View Article and Full-Text PDF
February 2022

Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.

J Chin Med Assoc 2021 11;84(11):993-1000

Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, and National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan, ROC.

Background: The mainstay therapy for latent tuberculosis infection is a 9-month regimen of daily isoniazid (9H) and a 3-month regimen of 12 once-weekly doses of isoniazid and rifapentine (3HP). We performed this updated meta-analysis to compare hepatotoxicity, efficacy and completion rate between these two regimens.

Methods: We searched all literature in the major medical databases using the subject search terms "isoniazid" and "rifapentine", and performed a systemic review and meta-analysis. Read More

View Article and Full-Text PDF
November 2021

High Burden of Adverse Drug Reactions to Isoniazid Preventive Therapy in People Living With HIV at 3 Tertiary Hospitals in Uganda: Associated Factors.

J Acquir Immune Defic Syndr 2022 02;89(2):215-221

Department of Pharmacology and Therapeutics, College of Health Sciences Makerere University, Kampala, Uganda.

Background: HIV is one of the most important risk factors of tuberculosis (TB)-related morbidity and mortality. Isoniazid preventive therapy (IPT) is recommended to prevent latent TB reactivation in patients with HIV. However, due to multiple therapies and comorbidities, these patients are predisposed to adverse drug reactions (ADRs) that lead to increased morbidity and mortality. Read More

View Article and Full-Text PDF
February 2022

Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases.

Clin Rheumatol 2022 Mar 24;41(3):889-897. Epub 2021 Oct 24.

Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

Introduction: Screening and treatment of latent tuberculosis infections (LTBI) are required before starting biologics in patients with immune-mediated inflammatory diseases (IMIDs). This study aimed to assess the safety of LTBI treatment in older patients with IMIDs.

Methods: The medical records of 916 patients treated for LTBI before the start of biologics for IMIDs between January 2004 and December 2018 were reviewed. Read More

View Article and Full-Text PDF

Toxicological evaluation of oral exposure to isoniazid: behavioral, biochemical, and histopathological assessments in rats.

Drug Chem Toxicol 2021 Sep 21:1-7. Epub 2021 Sep 21.

Research Unit n° 17/ES/12, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.

Isoniazid (INH), being the first-line drug used as an anti-tuberculosis drug, is known to be associated with physiological deteriorations including hepatic and neurologic disturbances. This study was aimed at biochemical and behavioral characterization of toxic manifestations of isoniazid treatment in rats. Experimental animals were divided into four groups. Read More

View Article and Full-Text PDF
September 2021

Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.

PLoS Med 2021 09 14;18(9):e1003738. Epub 2021 Sep 14.

Respiratory Epidemiology and Clinical Research Unit, McGill International TB Centre, McGill University, Montréal, Québec, Canada.

Background: Tuberculosis (TB) preventive therapy (TPT) is an essential component of care for people living with HIV (PLHIV). We compared efficacy, safety, completion, and drug-resistant TB risk for currently recommended TPT regimens through a systematic review and network meta-analysis (NMA) of randomized trials.

Methods And Findings: We searched MEDLINE, Embase, and the Cochrane Library from inception through June 9, 2020 for randomized controlled trials (RCTs) comparing 2 or more TPT regimens (or placebo/no treatment) in PLHIV. Read More

View Article and Full-Text PDF
September 2021

Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.

Mol Genet Genomic Med 2021 10 12;9(10):e1764. Epub 2021 Sep 12.

Instituto Nacional de Salud, Lima, Peru.

Background: We determined the frequency of genetic polymorphisms in three anti-TB drug metabolic proteins previously reported: N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1), and arylacetamide deacetylase (AADAC) within a Peruvian population in a cohort of TB patients.

Methods: We genotyped SNPs rs1041983, rs1801280, rs1799929, rs1799930, rs1208, and rs1799931 for NAT2; rs3813867 and rs2031920 for CYP2E1; and rs1803155 for AADAC in 395 participants completed their antituberculosis treatment.

Results: Seventy-four percent of the participants are carriers of slow metabolizer genotypes: NAT2*5, NAT2*6, and NAT2*7, which increase the sensitivity of INH at low doses and increase the risk of drug-induced liver injuries. Read More

View Article and Full-Text PDF
October 2021

Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors.

Sci Rep 2021 09 9;11(1):18013. Epub 2021 Sep 9.

Department of Internal Medicine, Division of Allergy, Immunology, and Rheumatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138 Shen-Li Rd., Tainan, 704, Taiwan.

To investigate associations between isoniazid for latent tuberculosis and risk of severe hepatitis, affecting patients with rheumatoid arthritis or ankylosing spondylitis whose treatment includes tumor necrosis factor inhibitors. Our self-controlled case series study analyzed Taiwan's National Health Insurance Database from 2003 to 2015 to identify RA or AS patients, aged ≥ 20 years, receiving TNF inhibitors and a 9-month single isoniazid treatment. The outcome of interest was hospitalization due to severe hepatitis. Read More

View Article and Full-Text PDF
September 2021

Anti-tuberculosis drug-induced acute liver failure requiring transplantation in the second trimester of pregnancy: a case report.

BMC Pregnancy Childbirth 2021 Aug 31;21(1):592. Epub 2021 Aug 31.

Department of Gynecology and Obstetrics, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79 Qingchun Road, 310003, Hangzhou City, Zhejiang Province, China.

Background: Treatment of tuberculosis (TB) during pregnancy can reduce maternal and foetal complications. However, it may also induce fatal liver injury.

Case Presentation: We present a case of a 26-year-old pregnant woman who underwent orthotopic liver transplantation for anti-TB drug-induced fulminant hepatic failure (FHF). Read More

View Article and Full-Text PDF

Hepatoprotective Effect of Corm of (Welw.) Cheesman Extract against Isoniazid and Rifampicin Induced Hepatotoxicity in Swiss Albino Mice.

J Toxicol 2021 13;2021:4760455. Epub 2021 Aug 13.

Division of Medical Biochemistry, Department of Biomedical Sciences, Institute of Health Sciences, Jimma University, Jimma, Ethiopia.

Drug-induced liver injury (DILI) is one of the cumbersome health-related problems which render approximately 50% of liver failure and patients to receiving liver transplantation every year. Antituberculosis drugs such as isoniazid and rifampicin are potentially rendering hepatotoxicity. (Welw. Read More

View Article and Full-Text PDF

The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country.

Transpl Infect Dis 2021 Oct 16;23(5):e13709. Epub 2021 Aug 16.

Sindh Institute of Urology and Transplantation, Karachi, Pakistan.

Introduction: Renal transplant recipients are at high risk of tuberculosis (TB). We started isoniazid (INH) prophylaxis of 1 year duration in all renal transplant recipients from April 2009. Our aim was to assess the incidence of TB on INH prophylaxis and its tolerability. Read More

View Article and Full-Text PDF
October 2021

Unusual Recurrence of Antituberculosis Drug-Induced Hepatotoxicity in Children: A Case Series.

Am J Case Rep 2021 Jul 16;22:e930828. Epub 2021 Jul 16.

Department of Child Health, Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.

BACKGROUND Antituberculosis drug-induced hepatotoxicity (ADIH) is a possible adverse event of antitubercular treatment. There are still no official guidelines for ADIH management in children. Recurrent ADIH is infrequently reported. Read More

View Article and Full-Text PDF

Genetic and Functional Evaluation of the Role of FOXO1 in Antituberculosis Drug-Induced Hepatotoxicity.

Evid Based Complement Alternat Med 2021 19;2021:3185874. Epub 2021 Jun 19.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Background: The accumulation of the hepatotoxic substance protoporphyrin IX (PPIX) induced by aminolevulinate synthase 1 (ALAS1) activation is one of the important mechanisms of antituberculosis drug-induced hepatotoxicity (ATDH). Forkhead box protein O1 (FOXO1) may activate ALAS1 transcription. However, little is known about their roles in ATDH; we performed a study to determine the association between polymorphisms in the two genes and ATDH susceptibility. Read More

View Article and Full-Text PDF

Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates.

Rheumatol Int 2021 Jul 6. Epub 2021 Jul 6.

Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Kocamustafapasa, Fatih, Istanbul, 34098, Turkey.

It is assumed that in candidates for TNF-alpha inhibitor (TNFi) treatment, tuberculin skin test (TST) may be unreliable, since BCG vaccination causes false positive and drugs cause false negative results, favoring the use of Quantiferon or T-spot assays. However, these tests may not be readily available in all parts of the world. We aimed to determine the reliability of TST with respect to BCG vaccination and drugs in candidates for TNFi treatment, and how isoniazid is tolerated, assuming that the use of TST would result in increased isoniazid use. Read More

View Article and Full-Text PDF

Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats.

BMC Pharmacol Toxicol 2021 07 3;22(1):39. Epub 2021 Jul 3.

Department of Biochemistry, Mount Carmel College, Bengaluru, India.

Background: The present study investigated the ameliorative effect of melittin, a major polypeptide in the venom of honeybee (Apis mellifera), on isoniazid-(INH) and rifampicin-(RIF) induced hepatotoxicity in male albino rats.

Method: Thirty rats (140-200 g) were divided into five groups (n = 6): normal control (NC) received normal saline orally (NaCl, 0.9%; toxic (T) group received INH + RIF (each rat received 100 mg/kg, p. Read More

View Article and Full-Text PDF

Lagerstroemia speciosa (L.) Pers., ethanolic extract attenuates simultaneously administered isoniazid- and dapsone-induced hepatotoxicity in rats.

J Food Biochem 2021 Jun 21:e13830. Epub 2021 Jun 21.

Department of Pharmacology, The Blue Lab, Molecular Medicine and Toxicology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, India.

Herbal tea of Lagerstroemia speciosa Pers., commonly known as banaba, has been traditionally used to treat various ailments including diabetes and obesity due to its antioxidant and anti-inflammatory efficacies. Drug-induced liver injury is a common cause of acute liver failure. Read More

View Article and Full-Text PDF

The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.

Ann Palliat Med 2021 Jun 18;10(6):6518-6534. Epub 2021 Jun 18.

Department of Nephrology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Background: Isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) are the four most common drugs for the first-line treatment of tuberculosis (TB). Although chemotherapy drugs are widely used in the treatment of TB, and achieved good results, but the side effects, especially anti-tuberculosis drug-induced liver injury (ATDILI), cannot be overlooked. Many researchers have made efforts to uncover the association of cytochrome P450 (CYP) enzyme genetic polymorphisms with ATDILI. Read More

View Article and Full-Text PDF